Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average recommendation of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $199.5333.

PVLA has been the topic of a number of research reports. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. BTIG Research boosted their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Mizuho upped their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th.

Insider Buying and Selling

In other news, Director Elaine J. Heron purchased 2,400 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were bought at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the purchase, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC boosted its stake in Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after purchasing an additional 271,617 shares during the period. Suvretta Capital Management LLC boosted its position in shares of Palvella Therapeutics by 8.5% during the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after acquiring an additional 70,000 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Palvella Therapeutics by 65.3% during the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after acquiring an additional 253,128 shares during the last quarter. Vanguard Group Inc. raised its holdings in Palvella Therapeutics by 13.3% during the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after buying an additional 65,960 shares during the period. Finally, State Street Corp raised its holdings in Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after buying an additional 283,211 shares during the period. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Trading Down 1.7%

Shares of PVLA stock opened at $113.99 on Friday. Palvella Therapeutics has a 12 month low of $20.20 and a 12 month high of $151.18. The stock has a market cap of $1.63 billion, a PE ratio of -27.34 and a beta of -0.13. The company’s fifty day moving average price is $121.93 and its 200-day moving average price is $105.45.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, sell-side analysts forecast that Palvella Therapeutics will post -5.43 earnings per share for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.